High Price of Weight-Loss Drugs Burdens Users, Analysis Reveals

The financial strain of weight-loss medications, specifically GLP-1s, is becoming increasingly evident, as a new analysis indicates that only high earners can realistically benefit from their use. According to consultancy Baringa, individuals need a discretionary income of approximately £100,000 annually to offset the £1,200 cost of these drugs through savings on grocery bills.

Paddy Winters, a partner at Baringa, described this situation as a "regressive tax on being thin," noting that the financial burden disproportionately affects those with lower incomes. While users with a leftover income of £39,000 can save around £481 on food annually, it takes a significantly higher income of £97,500 to truly benefit from the medication's cost.

Many users, who predominantly obtain the drugs through private prescriptions, find that the expenses associated with GLP-1s often exceed any grocery savings. As Winters pointed out, users also incur additional costs for supplements and personal care to manage side effects, which can add to their financial strain. The result is a cycle of starting and stopping the medication, leading to weight regain and potential debt.

In England, around 14.3 million adults are living with obesity, with estimates suggesting that nearly 3 million are currently on weight-loss medication. The charity King's Fund has urged for better accessibility to these treatments to prevent widening health inequalities.

Dr. Leyla Hannbeck from the Independent Pharmacies Association highlighted that NHS access to GLP-1s is restricted to a small group, leaving many unable to afford necessary care. Despite recent market growth and the introduction of new products, the high costs remain a significant barrier for most potential users.

Source: www.theguardian.com